Identified a new lead compound for anticancer therapy

Research of Prof. R. Žalubovskis group (LIOS) and scientists from Serbia (Institute for Biological Research “Sinisa Stankovic”; Institute of Nuclear Sciences VINCA ) and Russia (Saint Petersburg State University) has been published in European Journal of Medicinal Chemistry (IF  4.833, 2018) on new  thioredoxin reductase 1 (TrxR1) inhibitors.  Studies identified DVD-445 as a new lead compound for anticancer therapy.


Mirna Jovanović, Daniil Zhukovsky, Ana Podolski-Renić, Ilona Domračeva, Raivis Žalubovskis, Milan Senćanski, Sanja Glišić, Vladimir Sharoyko, TatianaTennikova, Dmitry Dar’in, Milica Pešić, Mikhail Krasavin.
Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy.
Eur. J. Med. Chem. 181, 2019, 111580, DOI: 10.1016/j.ejmech.2019.111580

The research was supported by the Russian Foundation for Basic Research (project grant 18–515-76001, Ministry of Education, Science and Technological Development of the Republic Serbia (project III41031), ERA.Net RUS plus joint program grant RUS_ST2017-309 and State Education Development Agency of Republic of Latvia (“THIOREDIN”). This work was also supported by a Short-Term Scientific Mission (STSM) Grant from COST Action CA17104 “New diagnostic and therapeutic tools against multidrug resistant tumors” and European Cooperation in Science and Technology.